Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received ...

Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...

Edwards Lifesciences (EW) announced the company’s Sapien M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

Edwards Lifesciences (NYSE:EW) announced today that it received CE mark approval for its Sapien M3 mitral valve replacement ...

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

The Irvine-based medical device maker today announced that it received CE mark approval for its Sapien M3 mitral replacement ...

Edwards Lifescienes also reported a big increase in pay for the structural heart device developer and manufacturer's median ...

Edwards Lifesciences Corp. closed 28.34% below its 52-week high of $95.25, which the company achieved on July 11th.

Shares of Edwards Lifesciences Corp. EW rose 1.67% to $69.40 Friday, on what proved to be an all-around great trading session ...

Truist lowered the firm’s price target on Edwards Lifesciences (EW) to $75 from $78 and keeps a Hold rating on the shares as part of a broad ...

Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $76.89, a high estimate of ...

Edwards Lifesciences Corporation (EW), a $39.4 billion medical technology firm based in Irvine, California, specializes in ...